Lawsuit filed for Investors who lost money with shares of RxSight, Inc. (NASDAQ: RXST)

An investor, who purchased shares of RxSight, Inc. (NASDAQ: RXST), filed a lawsuit over alleged violations of Federal Securities Laws by RxSight, Inc. in connection with certain allegedly false and misleading statements.

Investors who purchased shares of RxSight, Inc. (NASDAQ: RXST) have certain options and for certain investors are short and strict deadlines running. Deadline: September 22, 2025. NASDAQ: RXST investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

Aliso Viejo, CA based RxSight, Inc., a commercial-stage medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States. RxSight, Inc. (NASDAQ: RXST) reported that its annual Total Revenue rose from $89.07 million in 2023 to $139.92 million in 2024, and that its Net Loss declined from $48.6 million in 2023 to $27.45 million in 2024.

On July 8, 2025, after the market closed, RxSight, Inc. (NASDAQ: RXST) reported preliminary second quarter 2025 financial results, revealing significant declines in LDD sales, and LAL utilization, and overall revenue. The Company also lowered its full year 2025 guidance by approximately $42.5 million at the midpoint. The Company's Chief Executive Officer, Ronald Kurtz, also disclosed that "[a]doption challenges over the last few quarters have been a primary reason for the LDD stall."

Shares of RxSight, Inc. (NASDAQ: RXST) declined from $58.23 per share on August 26, 2024 to as low as $6.32 per share on July 9, 2025.

The plaintiff claims that between November 7, 2024 and July 8, 2025, the Defendants failed to disclose to investors that the Company was experiencing "adoption challenges" and/or structural issues resulting in declines in sales and utilization, that the Defendants had overstated the demand for RxSight's products, that as a result, RxSight was unlikely to meet its own previously issued financial guidance for fiscal year 2025, and that, as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Those who purchased shares of RxSight, Inc. (NASDAQ: RXST) have certain options and should contact the Shareholders Foundation.

Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.